English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, September 29, 2020
知臨集團開設傳染病液體活檢初創子公司,獨家獲得了新加坡Accelerate Technologies的許可以共同開發基於基因組分析以追蹤病原體基因組的快速分子病原體診斷技術
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary, Announces Exclusive In-license from Singapore-based Accelerate Technologies to Co-Develop Molecular Based Rapid Pathogen Diagnostics to Track Pathogenic Genome
Tuesday, September 8, 2020
Aptorum Group to Hold Investor Webinar and Present at The Wall Street Investor Forum on September 10
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
Tuesday, September 1, 2020
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020
Monday, July 27, 2020
Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM
Monday, March 30, 2020
知临集团与Covar医疗携手依托现有Smart-ACTTM平台和Acticule传染病平台研究至少3种2019冠状病毒肺炎(COVID-19)候选再利用药物(SACT-COV19)
知臨集團與Covar醫療攜手依託現有Smart-ACTTM平台和Acticule傳染病平台研究至少3種2019冠狀病毒肺炎(COVID-19)候選再利用藥物(SACT-COV19)

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575